《大行》里昂:康方生物(09926.HK)海外伙伴Summit(SMMT.US)获阿斯利康投资 利好依沃西全球发展

阿斯达克财经
Sep 29

里昂发表研究报告指,康方生物(09926.HK) 海外合作伙伴Summit Therapeutics(SMMT.US)  获阿斯利康(AZN.US)  投资,有利依沃西(ivonescimab)全球发展。该行指出,阿斯利康周一(28日)宣布向Summit Therapeutics优先股投资20亿美元,并探索依沃西与阿斯利康多款抗体偶联药物的联合用药方案。Summit是康方生物海外开发依沃西的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10